

Reference:	FOI.8276.22
Subject:	Use of certain drugs
Date of Request:	16 February 2022

Requested:

1. How many patients have been treated with the following drugs in the past 4 months:
 - Erenumab (Aimovig) - any disease
 - Fremanezumab (Ajovy) - any disease
 - Galcanezumab (Emgality) - any disease
 - Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY
2. I would like to understand the source of funding of Botox and anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality) for migraine. Could you please answer the following questions:
 - a. Does the trust commission/fund Botulinum Toxin treatment for migraine (Y/N)?
 - b. Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)?
 - c. In case the trust actively provides Botulinum Toxin treatment for migraine but does not commission/fund it, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.
 - d. In case the trust actively provides anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.

Response:

1. Hywel Health Board (UHB) is unable to provide you with all of the information requested for question 1, as it is estimated that the cost of answering your request would exceed the "appropriate limit" as stated in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. The "appropriate limit" represents the estimated cost of one person spending 18 hours (or 2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with all of the information requested, the UHB would need to undertake a manual search of all of the patients' records that were prescribed Botulinum Toxin, to identify those that received the medication for the treatment of migraine only, during the requested period, as this information is not recorded centrally. It is estimated that the cost of conducting this search would be:

103 records @ 15 minutes per record = 25.75 hours
 25.75 hours @ £25 per hour = £643.75

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, we are required as a public authority, to provide advice and assistance so far as it is reasonable, to individuals who have made a request under FoIA.

Therefore, the UHB provides, within the table below, the number of patients that have been treated with the listed medications, and the number of patients treated with Botulinum Toxin for all indications, during the period 1 October 2021 to 31 January 2022.

Medication	Number
Erenumab (Aimovig)	1
Fremanezumab (Ajovy)	17
Galcanezumab (Emgality)	0
Botulinum Toxin (i.e., Botox, Dysport, Xeomin)	103 – All indications

2a. The UHB confirms that it does commission/fund Botulinum Toxin treatment for migraine.

2b. The UHB confirms that it does commission/fund anti-CGRP treatments for migraine.

2c. Not applicable.

2d. Not applicable.